Combining Large Scale Biochemical and Cellular Profiling Data to Better Understand the Mechanism of Anti-Tumor Drugs

This poster is about elucidating the selectivity and cellular behavior of several marketed kinase inhibitors used in the treatment of cancer patients. Generally, kinase inhibitors are optimized to inhibit a single cellular target associated with cancer progression. However, most currently marketed kinase inhibitors interact with a highly conserved ATP binding site raising the question of their selectivity and therapeutic mechanism of action. Through EMD-Millipore’s KinaseProfiler™ service, the selectivity of Imatinib, Sunitinib, Lapatinib was profiled, as well as several other marketed kinase inhibitors against a panel of over 250 kinases.